Grade My Investments
HomeFree Stock Grades › VCEL

Vericel Corporation (VCEL) Stock Grade

VCEL · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.8B
P/E Ratio
110.3
Revenue Growth (YoY)
+16.5%
Net Margin
6.0%
Return on Equity
4.7%
Dividend Yield
None

About Vericel Corporation's fundamentals

Vericel is a biotechnology company with a $1.8 billion market capitalization that has demonstrated solid revenue growth of 16.5% year-over-year, indicating expanding business activity. However, the company trades at a notably elevated P/E ratio of 110.3, which reflects market expectations that may be optimistic relative to current earnings. With a net margin of 6.0% and a return on equity of 4.7%, profitability metrics remain modest, and the company does not currently pay a dividend to shareholders.

Track VCEL free — no credit card required. Live grade + monthly AI report →